GALAFAB: A Study of Migalastat in Fabry Disease
Study Details
Study Description
Brief Summary
Fabry disease is a rare metabolic condition characterised by the widespread deposition of sphingolipids in multiple organ systems. Cardiac involvement is common, it occurs in fifty percent of patients and it is the leading cause of death. Despite this, heart and blood vessel (cardiovascular system) manifestations of Fabry disease remain poorly characterised, and it remains unclear which patients benefit from therapy, or when therapy should be initiated. Migalastat is increasingly used to treat fabry disease however the impact of Migalastat on the cardiovascular system is poorly understood. Detailed assessment of the impact of Migalastat on heart and blood vessel structure and function is urgently needed. This observational study will use state of the art, non-invasive investigations to provide greater understanding of the cardiovascular manifestations of Fabry disease and the effects of Migalastat. It will provide insight into which patients respond more effectively to Migalastat, which in turn will facilitate personalisation of therapy, optimisation of the timing of therapy initiation and more cost-effective care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
This is a prospective longitudinal observational study of patients starting Migalastat as part of routine care. Participants will be recruited from outpatient clinics and have a number of investigations before starting therapy and after twelve months of therapy.
Investigations will include a detailed assessment of symptoms and clinical features, blood tests, echocardiography, detailed cardiac MRI scans, heart rhythm monitoring and exercise capacity assessment.
Parameters will be assessed at baseline and at twelve months.
Study Design
Outcome Measures
Primary Outcome Measures
- Indexed Left Ventricular Mass (grams/m2) [12 months]
LV mass, indexed to body surface area, assessed using cardiac MRI.
Secondary Outcome Measures
- Change in BSA-indexed LV volumes measured using cardiac MRI, from baseline to 12 months (mls/m2) [12 months]
- Change LV ejection fraction, measured using cardiac MRI (%) [12 months]
- Change in myocardial extracellular volume, measured using cardiac MRI (%) [12 months]
- Change in myocardial tissue T1 and T2 times measured using cardiac MRI (ms) [12 months]
- Change in pulmonary artery systolic pressure, measured using echocardiography (mmHg) [12 months]
- Change in myocardial PCr/ATP ratio, measured using cardiac MRI spectroscopy (ratio) [12 months]
- Change in the number of extra heart beats in a 24 hour period, measured using ambulatory heart monitoring. (number) [12 months]
- Change in exercise capacity - Six minute walk test (meters) [12 months]
- 20. Change in health status (quality of life), measured using change in SF-36 score. (score) [12 months]
- Change in Lyso-GB3 blood test levels (nmol/L) [12 months]
- Change in Troponin blood test levels (ng/L) [12 months]
- Change in NT pro BNP blood test levels (pg/L) [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
Confirmed Fabry disease Aged 16 or over Beginning clinical treatment with Migalastat
Exclusion Criteria:
Contraindication to cardiac MRI
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Manchester University Foundation Trust | Manchester | United Kingdom | M139LT | |
| 2 | Salford Royal NHS Foundation Trust | Manchester | United Kingdom | M6 8HD |
Sponsors and Collaborators
- Manchester University NHS Foundation Trust
- Northern Care Alliance NHS Foundation Trust
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- B00544
- 19/NW/0099